| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Medicine (B.M.P., T.D.R.), Epidemiology (A.L.F., B.M.P.), and Psychiatry (J.C.S.B.), University of Washington, Seattle; Veterans Affairs Puget Sound Health Care System (J.C.S.B.), Seattle; Department of Epidemiology (L.H.K.), University of Pittsburgh School of Medicine, PA; and Department of Mental Health (C.A.S., P.P.Z.), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
* To whom correspondence should be addressed. E-mail: pzandi{at}jhsph.edu.
ABSTRACT
Background: Epidemiologic and laboratory studies suggest that nonsteroidal antiinflammatory drugs (NSAIDs) reduce risk of Alzheimer disease (AD). We therefore investigated the association between use of NSAIDs, aspirin, and the non-NSAID analgesic acetaminophen with incidence of dementia and AD.
Methods: Participants in the Cardiovascular Health Cognition Study included 3,229 individuals aged 65 or older, free of dementia at baseline, with information on medication use. We used Cox proportional hazards regression to estimate the association of medication use with incident all-cause dementia, AD, and vascular dementia (VaD). Additional analyses considered the NSAID–AD relationship as a function of age, presence of at least one 
4 allele at APOE, race, and individual NSAIDs’ reported ability to reduce production of the amyloid–beta peptide variant A
42.
Results: Use of NSAIDs was associated with a lower risk of dementia (adjusted hazard ratio or aHR 0.76, 95% CI or CI 0.60–0.96) and, in particular, AD (aHR 0.63, CI 0.45–0.88), but not VaD (aHR 0.92, CI 0.65–1.28). No similar trends were observed with acetaminophen (aHR 0.99, CI 0.79–1.24). Closer examination suggested AD risk reduction with NSAIDs only in participants having an APOE 4 allele (aHR 0.34, CI 0.18–0.65; aHR for others 0.88, CI 0.59–1.32). There was no advantage in AD risk reduction with NSAIDs reported to selectively reduce A42.
Conclusions: Results were consistent with previous cohort studies showing reduced risk of AD in NSAID users, but this association was found only in those with an APOE 4 allele, and there was no advantage for A42-lowering NSAIDs.
This article has been cited by other articles:
|
|
 |
|
  N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand Dementia Prevention: Methodological Explanations for Inconsistent Results Epidemiol. Rev., November 1, 2008; 30(1): 35 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al. No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies Neurology, June 10, 2008; 70(24): 2291 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al. Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity Brain, March 1, 2008; 131(3): 651 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rogers and M. N. Sabbagh Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk Neurology, January 1, 2008; 70(1): 5 - 6. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
